Catriona Yale Sells 9,061 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 9,061 shares of the stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $27.73, for a total value of $251,261.53. Following the sale, the insider now directly owns 74,158 shares of the company’s stock, valued at approximately $2,056,401.34. This trade represents a 10.89 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Catriona Yale also recently made the following trade(s):

• On Friday, November 1st, Catriona Yale sold 15,485 shares of Akero Therapeutics stock. The shares were sold at an average price of $32.62, for a total transaction of $505,120.70.
• On Wednesday, October 30th, Catriona Yale sold 4,515 shares of Akero Therapeutics stock. The shares were sold at an average price of $32.53, for a total value of $146,872.95.
• On Monday, October 14th, Catriona Yale sold 6,136 shares of Akero Therapeutics stock. The shares were sold at an average price of $30.03, for a total transaction of $184,264.08.
• On Friday, September 20th, Catriona Yale sold 5,500 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.65, for a total transaction of $152,075.00.
• On Wednesday, September 18th, Catriona Yale sold 3,871 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.56, for a total transaction of $106,684.76.
• On Monday, September 16th, Catriona Yale sold 2,485 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.52, for a total value of $68,387.20.
• On Tuesday, September 10th, Catriona Yale sold 637 shares of Akero Therapeutics stock. The stock was sold at an average price of $26.18, for a total value of $16,676.66.
• On Friday, August 23rd, Catriona Yale sold 8,851 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.53, for a total value of $243,668.03.
• On Monday, August 26th, Catriona Yale sold 5,200 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.51, for a total transaction of $143,052.00.

Akero Therapeutics Price Performance

NASDAQ AKRO opened at $30.64 on Thursday. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. Akero Therapeutics, Inc. has a 1-year low of $15.32 and a 1-year high of $37.00. The stock has a market capitalization of $2.14 billion, a price-to-earnings ratio of -8.17 and a beta of -0.26. The business’s fifty day moving average price is $29.73 and its 200-day moving average price is $25.85.

Akero Therapeutics (NASDAQ:AKRO) last released its quarterly earnings results on Friday, November 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15). On average, equities analysts predict that Akero Therapeutics, Inc. will post -3.96 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on AKRO shares. Citigroup assumed coverage on shares of Akero Therapeutics in a report on Monday. They issued a “buy” rating and a $65.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Akero Therapeutics in a research note on Monday. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $46.83.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. lifted its position in Akero Therapeutics by 2,366.0% during the first quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock valued at $31,000 after purchasing an additional 1,183 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Akero Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock worth $71,000 after acquiring an additional 446 shares in the last quarter. Eastern Bank bought a new stake in Akero Therapeutics during the 3rd quarter worth approximately $100,000. Ameritas Investment Partners Inc. lifted its holdings in Akero Therapeutics by 20.0% during the first quarter. Ameritas Investment Partners Inc. now owns 6,175 shares of the company’s stock valued at $156,000 after purchasing an additional 1,030 shares in the last quarter. Finally, Summit Financial Wealth Advisors LLC bought a new position in shares of Akero Therapeutics in the third quarter worth approximately $205,000.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.